COVID-19 vaccine doses and administration
There are 4 COVID-19 vaccines approved for use in Australia. Find out their dosage, volume and schedules.
Comirnaty – generic name Tozinameran or BNT162b2
|
Category |
Detail |
|---|---|
|
Sponsor |
Pfizer Australia Pty Ltd |
|
Approved age for use |
≥12 years |
|
Presentation |
Multidose vial without preservative. Each vial containing 6 doses in 0.45mL. Requires dilution with 1.8 mL of sterile 0.9% NaCl without preservative into each multidose vial |
| Cap colour | Purple |
|
Volume/strength |
0.3 mL (30 µg) per dose |
|
Schedule |
2 dose, 3-8 weeks apart apart |
|
Administration route |
Intramuscular injection into deltoid muscle |
|
Ingredients |
Each 0.3 mL dose contains 30 µg mRNA encoding the SARS-CoV-2 spike glycoprotein |
|
Excipients |
|
Paediatric Comirnaty (5 – 11 formulation) – generic name Tozinameran or BNT162b2
|
Category |
Detail |
|---|---|
|
Sponsor |
Pfizer Australia Pty Ltd |
|
Approved age for use |
5 to <12 years |
|
Presentation |
Tris/Sucrose presentation. Multidose vial containing 10 doses in 1.3mL. Requires dilution with 1.3 mL of sterile 0.9% NaCl without preservative into each multidose viall |
| Cap colour | Orange |
|
Volume/strength |
0.2 mL (10 µg) per dose |
|
Schedule |
2 doses, 8 weeks apart |
|
Administration route |
Intramuscular injection into deltoid muscle |
|
Ingredients |
Each 0.2 mL dose contains 10 µg mRNA encoding the SARS-CoV-2 spike glycoprotein |
|
Excipients |
|
Spikevax (Moderna) – generic name Elasomeran or mRNA-1273
|
Category |
Detail |
|---|---|
|
Sponsor |
Moderna Australia Pty Ltd |
|
Approved age for use |
≥6 years |
|
Presentation |
Multidose vial without preservative, each vial containing 10 full doses in 5 mL |
|
Volume/strength |
For children aged 6 to 11 years: 0.25 mL per dose For people aged ≥12 years as a primary course: 0.5 mL per dose For people aged ≥18 years as a booster: 0.25 mL per dose |
|
Schedule |
For children aged 6 to 11 years: 2 doses, 8 weeks apart For people aged ≥12 years: 2 doses, 4-8 weeks apart |
|
Administration route |
Intramuscular injection into deltoid muscle |
|
Ingredients |
Each 0.5 mL dose contains 100 μg mRNA encoding the SARS-CoV-2 spike glycoprotein (50 ug in each 0.25 mL dose) |
|
Excipients |
|
Vaxzevria (AstraZeneca) – generic name ChAdOx1s
|
Category |
Detail |
|---|---|
|
Sponsor |
AstraZeneca Pty Ltd |
|
Approved age for use |
≥18 years |
|
Presentation |
Multidose vial without preservative, each vial containing either 8 doses in 4 mL or 10 doses in 5 mL |
|
Volume/strength |
0.5 mL per dose |
|
Schedule |
2 doses, 4 to 12 weeks apart |
|
Administration route |
Intramuscular injection into deltoid muscle |
|
Ingredients |
Each 0.5 mL dose contains 5 x 1010 viral particles of ChAdOx1-S, a recombinant, non-replicating chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein |
|
Excipients |
|
Nuvaxovid (Novavax)– generic name NVX-CoV2373
|
Category |
Detail |
|---|---|
|
Sponsor |
Biocelect Pty Ltd on behalf of Novavax Ltd |
|
Approved age for use |
≥18 years |
|
Presentation |
Multidose vial without preservative, each vial containing 10 doses in 5 mL |
|
Volume/strength |
5 µg antigen, 50 µg Matrix-M |
|
Schedule |
2 doses, 3-8 weeks apart |
|
Administration route |
Intramuscular injection into deltoid muscle |
|
Ingredients |
Each 0.5 mL dose contains 5 µg of SARS-CoV-2 spike protein, adjuvanted with Matrix-M. Adjuvant Matrix-M contains Fraction-A (42.5 µg) and Fraction-C (7.5 µg) of Quillaja saponaria Molina extract |
|
Excipients |
|